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SHORT COMMUNICATION
No association between major depression with and without childhood 
adversity and the stress hormone copeptin
Michael Kaczmarczyk a, Carsten Spitzer b, Katja Wingenfeld a, Klaus Wiedemannc, Linn K. Kuehla, 
Katharina Schultebraucksd, Christian Eric Deutera and Christian Ottea
aDepartment of Psychiatry and Psychotherapy, Campus Benjamin Franklin, Charité, Universitätsmedizin Berlin, Corporate member of 
Freie Universität Berlin, Humboldt-Universität zu Berlin, Berlin Institute of Health, Berlin, Germany; bDepartment of Psychosomatic 
Medicine, University Medicine Rostock, Rostock, Germany; cDepartment of Psychiatry and Psychotherapy, University Medical Center 
Hamburg-Eppendorf, Hamburg, Germany; dVagelos School of Physicians and Surgeons, Department of Emergency Medicine, Columbia 
University Irving Medical Center, New York, NY, USA
ABSTRACT
Background: Adverse childhood experiences (ACE) are associated with an increased risk of 
major depressive disorder (MDD) and hypothalamic-pituitary-adrenal (HPA) axis dysregula-
tion. Within the HPA axis, corticotropin-releasing hormone and vasopressin (AVP) synergis-
tically stimulate the release of adrenocorticotropic hormone, which promotes cortisol 
release. The cleavage product copeptin is produced during AVP synthesis and is 
a surrogate marker of AVP release. Children with ACE and young adults with depressive 
symptoms have higher levels of copeptin than healthy controls.
Objective: To uncover the effects of MDD and ACE on copeptin levels in adult females.
Methods: We recruited 94 women (mean age: 34.0 ± 3.6 years): 23 with MDD and ACE, 24 
with MDD without ACE, 22 with ACE without MDD, and 25 healthy controls. ACE was 
defined as repeated sexual or physical abuse at least once a month over at least one year 
before the age of 18 years. MDD was defined by the DSM-IV criteria. Copeptin plasma levels 
were measured with an immunoluminometric assay.
Results: The four groups did not differ in demographic variables. We found a significant 
negative correlation between body mass index (BMI) and copeptin plasma levels (r = −.21; 
p = .045). Copeptin plasma levels did not differ between the four groups after controlling for 
BMI.
Conclusion: Neither MDD nor ACE was associated with altered plasma copeptin levels. Thus, 
copeptin does not seem to play a major role in MDD and ACE in adult females.
No hay asociación entre la depresión mayor con y sin adversidad 
infantil y la hormona del estrés copeptina 
Antecedentes: Las experiencias adversas de la infancia (EAI) se asocian con un mayor riesgo 
de trastorno depresivo mayor (TDM) y desregulación del eje hipotalámico-pituitario-adrenal 
(HPA). Dentro del eje HPA, la hormona liberadora de corticotropina y la vasopresina (AVP) 
estimulan sinérgicamente la liberación de la hormona adrenocorticotrópica, que promueve 
la liberación de cortisol. El producto de escisión copeptina se produce durante la síntesis de 
AVP y es un marcador sustituto de la liberación de AVP. Los niños con EAI y los adultos 
jóvenes con síntomas depresivos tienen niveles más altos de copeptina que los controles 
sanos.
Objetivo: Descubrir los efectos del TDM y la EAI en los niveles de copeptina en mujeres 
adultas.
Métodos: Se reclutaron 94 mujeres (edad media: 34,0 ± 3,6 años): 23 con TDM y EAI, 24 con 
TDM sin EAI, 22 con EAI sin TDM y 25 controles sanos. La EAI se definió como abuso sexual 
o físico repetido al menos una vez al mes durante al menos un año antes de los 18 años. El 
TDM fue definido por los criterios del DSM-IV. Los niveles plasmáticos de copeptina se 
midieron con un ensayo inmunoluminométrico.
Resultados: Los cuatro grupos no difirieron en las variables demográficas. Encontramos una 
correlación negativa significativa entre el índice de masa corporal (IMC) y los niveles 
plasmáticos de copeptina (r = −.21; p = .045). Los niveles plasmáticos de copeptina no 
difirieron entre los cuatro grupos después de controlar el IMC.
Conclusión: Ni el TDM ni la EAI se asociaron con niveles alterados de copeptina plasmática. 
Por tanto, la copeptina no parece desempeñar un papel importante en el TDM y la EAI en 
mujeres adultas.
有无童年期不良经历的重性抑郁与应激激素肽素之间没有关联 
背景:童年期不良经历 (ACE) 与重性抑郁障碍 (MDD) 和下丘脑-垂体-肾上腺 (HPA) 轴失调的 
风险增加有关。在HPA轴内, 促肾上腺皮质激素释放激素和加压素 (AVP) 协同刺激促肾上 
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方法:我们招募了94名女性 (平均年龄:34.0±3.6岁):23名具有MDD和ACE, 24名具有MDD无 
ACE, 22名具有ACE无MDD和25名健康对照。 ACE被定义为在18岁之前的至少一年内, 每月 
至少经历一次的重复性的性虐待或身体虐待。 MDD由DSM-IV标准定义。用免疫荧光分析 
测定了血浆肽素水平。
结果:四组人口统计学变量无差异。我们发现, 体重指数 (BMI) 与血浆肽素水平之间存在显 




Activation of the hypothalamic-pituitary-adrenal (HPA) 
axis by physiological or psychosocial stressors stimulates 
the release of corticotropin-releasing hormone (CRH) 
from the hypothalamus, which in turn stimulates adre-
nocorticotropic hormone (ACTH) production, thus pro-
moting cortisol secretion. The hypothalamic hormone 
vasopressin (AVP), synergistically with CRH, stimulates 
the secretion of ACTH and cortisol (Katan & Christ- 
Crain, 2010). Measuring CRH and AVP levels to monitor 
stress-mediated activation of the HPA axis is challenging 
because they are released in a pulsatile pattern, are bio-
chemically unstable, and are rapidly degraded and cleared 
from plasma within minutes. The 39 amino acids glyco-
peptide copeptin, a cleavage product of AVP synthesis, is 
more stable at room temperature and easier to measure in 
plasma (Katan & Christ-Crain, 2010; Morgenthaler, 
Struck, Alonso, & Bergmann, 2006; Spanakis, Wand, Ji, 
& Golden, 2016). Copeptin levels are elevated in many 
severe medical conditions, including acute myocardial 
infarction and stroke (Katan & Christ-Crain, 2010; 
Lewandowski & Brabant, 2016), an effect attributable to 
increased AVP levels in response to stress.
Research on the link between psychosocial stress and 
copeptin is just emerging. Median copeptin and median 
cortisol levels were increased in a group of healthy sub-
jects immediately after the Trier Social Stress Test (TSST) 
(mean age: 22.5 years) (Siegenthaler, Walti, Urwyler, 
Schuetz, & Christ-Crain, 2014). Spanakis et al. (2016) 
reported higher baseline copeptin levels in men com-
pared with women. After the TSST, the authors found 
a positive association between the percent change in 
copeptin levels and cortisol in men, but not in women. 
Administration of the panicogenic peptide cholecystoki-
nin-tetrapeptide (CCK-4) induced copeptin release, 
which correlated with panic symptoms and secretion of 
ACTH and cortisol in non-obese men (mean age: 
27.4 years) (Demiralay et al., 2017). In another study, 
Schinke et al. (2017) measured copeptin after dexametha-
sone administration and before CRH administration in 
the combined dexamethasone/CRH stimulation test. 
Copeptin levels were higher in obese subjects (mean 
age: 36.5 ± 10.0 years; body mass index (BMI): 
41.5 ± 4.7 kg/m2) than normal-weight controls after 
dexamethasone administration. In the obese group, 
copeptin correlated positively with BMI, but not with 
age. Moreover, copeptin serum concentrations correlated 
positively with ACTH and cortisol curve indicators in 
obese men but not in non-obese controls and females, 
suggesting an interaction of the AVP system with HPA 
activation in obese men (Schinke et al., 2017).
Investigations of copeptin in stress-related disor-
ders are scarce. Major depressive disorder (MDD) 
and adverse childhood experiences (ACE) such as 
abuse and neglect have complex und unfavourable 
long-term effects on both mental and physical health 
(Otte et al., 2016), which might be partially explained 
by HPA axis dysfunction (De Bellis & Zisk, 2014). 
Depressive symptoms were associated with copeptin 
plasma concentrations in young adults (mean age: 
24.3 ± 2.97 years; female: 52.4%), with no differences 
between men and women (Thomsen et al., 2019). In 
another study, plasma copeptin concentrations were 
not significantly different between depressed subjects 
(mean age: 41.9 ± 11.2 years; female: 68.2%) and 
healthy controls (mean age: 40.6 ± 13.1 years; female: 
64.9%), and no association was observed between 
copeptin and cortisol or ACTH (Krogh et al., 2013). 
Despite growing evidence for a role of copeptin in 
psychosocial stress, only one study has investigated 
whether copeptin is associated with the negative 
effects of ACE (Coelho et al., 2016), and showed 
that serum copeptin levels were higher in children 
with ACE than in children without ACE.
MDD and ACE are associated with sex-specific dif-
ferences (McLean, Asnaani, Litz, & Hofmann, 2011). 
Women show higher prevalence rates for both, as well 
as higher symptom severity and comorbidity rates 
(Breslau, 2002). This contrasts with the lack of literature 
in this field and is underpinned by the vast heterogene-
ity and inconclusiveness of the available data. 
Therefore, the primary objective of our full-factorial 
explorative study was to investigate the association 
between MDD with and without ACE and copeptin in 
physically healthy females. Moreover, as most findings 
were reported in children (e.g. Coelho et al., 2016) or 
young adults (e.g. Thomsen et al., 2019), we opted for 
adult women in order to extend the literature in this 
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population, since ACE has repeatedly been associated 
with mental impairments and disorders in later life 
(Gould et al., 2012; Kaczmarczyk, Wingenfeld, Kuehl, 
Otte, & Hinkelmann, 2018; Majer, Nater, Lin, Capuron, 
& Reeves, 2010; Pechtel & Pizzagalli, 2011). We 
hypothesized that plasma levels of copeptin would be 
positively correlated with MDD and ACE. Since a body 
of work shows immediate copeptin changes following 
a stressor task, a secondary aim was to analyse the 
effects of acute physiological stress on copeptin using 
the combined dexamethasone/CRH stimulation test, 
assuming that cortisol response markers would be posi-
tively associated with copeptin.
2. Methods and material
2.1. Participants
Our participants were part of the sample from 
a previously published study (Spitzer et al., 2017), 
and copeptin data were available for these participants. 
Ninety-four women were included: 23 with MDD and 
ACE (MDD +/ACE +), 24 with MDD without ACE 
(MDD +/ACE –), 22 with ACE but no current or 
lifetime MDD (MDD – /ACE +), and 25 healthy 
controls with no current or lifetime mental disorder 
and with no experiences of abuse (MDD – /ACE –).
2.2. Clinical assessment
All participants underwent a comprehensive clinical 
assessment including the Structured Clinical 
Interview for DSM-IV axis I and axis II conducted 
by a consultant psychiatrist or a licenced psychologi-
cal psychotherapist.
Subjects with MDD met the clinical criteria for 
a DSM-IV diagnosis of current major depressive epi-
sode based on the SCID-I. Exclusion criteria included 
schizophrenia, schizoaffective and bipolar disorder, 
depressive episodes with psychotic features, posttrau-
matic stress disorder, anorexia, and substance depen-
dence. Depression was measured using the Beck 
Depression Inventory (BDI-II) based on the self-report 
and clinician-rated Montgomery–Åsberg Depression 
Rating Scale (MADRS).
ACE was defined as repeated sexual or physical 
abuse at least once a month over at least one year 
before the age of 18 years (Heim et al., 2000b). The 
presence of ACE was determined in clinical inter-
views. Afterwards, severity was assessed psychometri-
cally using the German version of the retrospective 
self-rated Childhood Trauma Questionnaire (CTQ) 
(Bernstein et al., 2003; Wingenfeld et al., 2010). 
Additionally, all subjects were interviewed using the 
Early Trauma Inventory (ETI) (Bremner, Vermetten, 
& Mazure, 2000; Wingenfeld et al., 2011).
Healthy controls also completed all clinical inter-
views and self-report questionnaires in the same 
manner as described above. No participant of either 
MDD – group had any current or lifetime mental 
disorder based on DSM-IV criteria. In order to be 
considered for either ACE – group (i.e. MDD 
+/ACE – and healthy controls), the participant had 
to be free of any adverse life event until the date of 
testing. This was ensured by extensive clinical inter-
views, checking for each of the main traumatic 
experiences (for example sexual harassment, physical 
abuse, accidents, war or natural disasters among 
many others). In case one participant reported 
a mild experience it was thoroughly investigated, 
whether this had any lasting effects or consequences 
for the subject. If this was the case, the participant 
was either excluded from participation, or, based on 
the criteria mentioned above, considered for one of 
the ACE + groups (resulting in two highly differing 
ACE +/ACE – groups).
Further exclusion criteria included neurological 
and severe metabolic, endocrine, or autoimmune dis-
eases, current infections, pregnancy, and a BMI above 
30 (since it is widely established that obesity is asso-
ciated with a plethora of metabolic and endocrine 
changes).
2.3. Procedure
The study took place at the Department of Psychiatry 
and Psychotherapy (Campus Benjamin Franklin) of 
Charité – Universitätsmedizin Berlin. Participants 
were recruited via public postings and through affec-
tive disorder units. All subjects provided written 
informed consent and received monetary remunera-
tion (€ 200 for the whole study). The study was 
approved by the local ethics committee. Blood sam-
ples were collected in the laboratory at 8 a.m. after an 
overnight fast (blood was taken with participants in 
the supine position and after rest for the same time 
before starting).
2.4. Combined dexamethasone/CRH stimulation 
test
In the combined dexamethasone/CRH stimulation test 
(performed on a separate day) all subjects received 
dexamethasone (oral; 1.5 mg) at 11:00 p.m. on the 
first study day and human CRH (intravenous; 100 μg) 
at 2:30 p.m. on the second study day. Salivary cortisol 
was collected using salivettes before (−60 min, −30 min, 
immediately before CRH infusion) and after (+30 min, 
+60 min, +90 min, +120 min) CRH infusion. Cortisol 
response markers were baseline to peak (BtP; difference 
between the mean of the three baseline cortisol mea-
sures and the maximum value after CRH) and area 
under the curve (AUC; computed with respect to 
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ground) values (for further information see Spitzer 
et al., 2017).
2.5. Hormonal measures
Copeptin: Blood samples with EDTA added were 
placed on ice, immediately centrifuged at 4°C, and 
stored at −80°C until analysis. Copeptin concentra-
tions were measured in the neurobiological laboratory 
of the Department of Psychiatry and Psychotherapy of 
the University Medical Centre Hamburg-Eppendorf 
using an immunoluminometric assay (B·R·A·H·M·S 
GmbH, Hennigsdorf, Berlin, Germany). Intra- and 
interassay coefficients of variation were below 4% 
and 7%, respectively. The detection limit was 1 pmol/l.
Cortisol: Salivary samples were stored at −80°C until 
analysis. Concentrations of free cortisol were measured 
in the neurobiological laboratory of the Department of 
Psychiatry and Psychotherapy, Campus Benjamin 
Franklin, Charité – Universitätsmedizin Berlin. Intra- 
and interassay coefficients of variation were below 8% 
and 10%, respectively. All samples and standards were 
measured in duplicates.
2.6. Data analysis
Continuous variables were analysed with ANOVA and 
categorical variables with Chi2 tests. Correlations were 
tested between copeptin and clinical parameters includ-
ing age, BMI, clinician- and self-reported depression 
scales, clinician- and self-reported childhood trauma 
scales, and cortisol response markers of the combined 
dexamethasone/CRH stimulation test (BtP and AUC 
values). We performed a 2 (MDD +, MDD –) × 2 
(ACE +, ACE –) ANCOVA with BMI as a covariate to 




Demographic and clinical data are shown in Table 1. 
The four groups did not differ significantly in age, 
BMI, smoking, years of education, and intake of oral 
contraceptives. Some women with MDD received 
antidepressants, but there was no significant differ-
ence in medication intake between the non-ACE and 
ACE group. Psychiatric comorbidities are presented 
in Table 1. No participants in the MDD – /ACE + 
group and no healthy controls had a mental disorder 
according to DSM-IV criteria. The MDD groups did 
not differ significantly in MADRS and BDI-II scores, 
but exhibited higher scores than both non-MDD 
groups did. CTQ and ETI sum scores were higher 
in both ACE groups than in the non-ACE groups.
Table 1. Sample characteristics of women with MDD with and without ACE and healthy women with and without ACE.
MDD +/ACE + 
(N = 23)
MDD +/ACE – 
(N = 24)
MDD – /ACE + 
(N = 22)
MDD – /ACE – 
(N = 25) statistics
Age Years 32.74 (10.6) 35.79 (10.4) 35.68 (11.5) 32.00 (11.2) p = .521
Years of education 11.09 (1.5) 11.13 (1.4) 11.50 (1.3) 11.70 (1.3) p = .420
Body mass index kg/m2 22.45 (3.3) 22.62 (4.2) 24.07 (3.3) 21.51 (3.2) p = .108
Smoking Yes/No 11/12 8/16 6/16 6/19 p = .317
Intake of oral contraceptives Yes/No 7/16 8/16 5/17 7/18 p = .879









MADRS Sum score 32.91 (6.7) 29.67 (6.6) 2.77 (2.3) 0.52 (0.9) p < .001
BDI-II Sum score 26.39 (10.6) 26.92 (8.0) 9.42 (7.1) 2.76 (3.1) p < .001
Anxiety
STAI trait Sum score 47.52 (4.7) 48.93 (6.1) 42.05 (5.9) 41.60 (2.4) p < .001
Adverse childhood experiences
ETI Sum score 578.61 (352.77) 388.20 (377.30) 710.05 (334.89) 23.80 (43.49) p < .001
CTQ Sum score 62.63 (16.3) 46.12 (14.0) 65.86 (19.2) 28.33 (3.5) p < .001
Copeptin pmol/l (SEM) 4.70 (0.64) 4.58 (1.01) 4.70 (0.52) 4.36 (0.56) p = .982
Abbreviations 
MDD +/ACE + = MDD subjects with ACE, MDD +/ACE – = MDD subjects without ACE, MDD – /ACE + = subjects with ACE but no MDD, MDD – 
/ACE – = healthy controls, BMI = body mass index, OC = oral contraceptives, SNRI = serotonin and noradrenaline reuptake inhibitor, SSRI = selective 
serotonin reuptake inhibitor, NDRI = dopamine and noradrenaline reuptake inhibitor, BDI-II = Beck Depression Inventory, MADRS = Montgomery- 
Åsberg Depression Rating Scale, STAI = State-Trait Anxiety Inventory, ETI = Early Trauma Inventory, CTQ = Childhood Trauma Questionnaire, 
SEM = standard error of the mean. 
Anticonvulsants: pregabalin 
a3 subjects had 2 drugs. 
b1 subject had 2 drugs. 
MDD +/ACE +: 9 subjects reported psychiatric comorbidities (6 subjects with persistent depressive disorder, 2 subjects with panic disorder, 1 subject 
with social anxiety disorder) 
MDD +/ACE –: 8 subjects reported psychiatric comorbidities (2 subjects with agoraphobia, 1 subject with borderline personality disorder, 2 subjects 
with persistent depressive disorder, 3 subjects with social anxiety disorder) 
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3.2. Correlations between copeptin and 
demographic variables
BMI correlated negatively with plasma copeptin 
(r = −.21; p < .045) (Figure 1(a)), so we included 
BMI in all further analyses. Other demographic vari-
ables (including age) did not significantly correlate 
with copeptin levels.
No psychopathology scores correlated significantly 
with copeptin (MADRS: r = −.048; p = .653; BDI-II: 
r = −.047; p = .663; STAI trait: r = −.040; p = .707; 
ETI: r = −.039; p = .711; CTQ: r = −.124; p = .243).
3.3. Effects on copeptin
2 × 2 ANCOVA with BMI as a covariate did not reveal 
a significant main effect of MDD (F(1,85) = .017; 
p = .895) or ACE (F(1,85) = .490; p = .486) on copeptin 
plasma levels (Figure 1(b)). The interaction between 
MDD and ACE was not significant (F(1,85) = .292; 
p = .590).
Exploratory analyses for the overall sample 
revealed a significant negative correlation between 
copeptin and the cortisol response markers of the 
combined dexamethasone/CRH stimulation test 
(BtP: r = −.231; p = .031; AUC: r = −.225; p = .036).
Figure 1. (a) Negative correlation between body mass index (BMI) and plasma copeptin levels in the overall sample. (b) Mean 
plasma copeptin levels. A 2 × 2 ANCOVA with BMI as covariate revealed no main effect of MDD or ACE, nor a significant MDD by 
ACE interaction effect. Depiction of mean value and standard error of the mean.
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4. Discussion
In this study, we did not detect any significant asso-
ciation between copeptin and MDD or a history of 
ACE in an adult, all-female sample.
Our finding that copeptin levels are not altered in 
individuals with MDD agree with those of Krogh et al. 
(2013), who found no difference in copeptin levels 
between depressed patients and healthy subjects. We 
expand these findings by including ACE in the present 
study. Our finding that copeptin levels are not altered in 
individuals with ACE is in contrast to a cross-sectional 
investigation which showed higher serum copeptin levels 
in children with ACE compared with controls, indepen-
dent of age, sex, and symptom severity (Coelho et al., 
2016). The design of this previous study was very similar 
to ours – the inclusion criteria were similar (i.e. good 
physical health, history of either moderate to severe ACE 
or no ACE) and the sample sizes of the ACE + and ACE – 
groups were similar too. The similar design suggests that 
this discrepancy may be explained by an influence of age; 
this should be investigated in future studies. Another 
possible explanation could be sex-related differences, as 
Coelho et al. (2016) included males and females in their 
study (ACE +: 47.8% female; ACE – : 52.2% female) 
whereas we only included females.
Our all-female sample was different to the mixed 
samples investigated by Thomsen et al. (2019) and 
Coelho et al. (2016). Not only basal copeptin concen-
trations (Burckhardt et al., 2014) but also the effects 
of stress on copeptin levels (Spanakis et al., 2016) 
seem to be sex-specific and thus are different in 
males and females. Copeptin levels were significantly 
lower in women than men before CCK-4 was applied 
to induce panic-like symptoms, while men showed 
a significantly higher increase of copeptin levels after 
CCK-4 was administered (Kellner et al., 2019). We 
decided to study an all-female population to elimi-
nate any sex-specific effects and determine whether 
copeptin levels are altered in female individuals with 
MDD and ACE.
Copeptin levels correlated negatively with BMI in 
our study; as BMI increased, copeptin plasma con-
centrations decreased. In another study, a positive 
correlation between copeptin levels and BMI was 
observed in obese males, but not in women and non- 
obese controls (Schinke et al., 2017).
Exploratory analyses revealed a negative correlation 
between copeptin levels and cortisol increase (measured 
by BtP and AUC values in the combined dexametha-
sone/CRH stimulation test). Schinke et al. (2017) found 
that copeptin levels (after dexamethasone) correlated 
positively with ACTH and cortisol release in obese 
males but not in females.
There are strengths and limitations to our study. We 
studied a homogeneous sample of female subjects. As 
described above, all diagnoses ware based on extensive 
clinical interviews. Our full-factorial study design 
allowed us to infer conclusions on the differential 
effects of MDD and ACE. However, we cannot general-
ize our findings to men. The literature on the associa-
tion between psychosocial stress and stress-related 
disorders with copeptin generally shows immediate 
effects (i.e. following a stressor task) in males. We 
decided to investigate adult females due to the pre-
viously mentioned sex-specific differences in MDD 
and ACE. Therefore, future studies should further 
investigate whether affected persons of different sex 
and age show the same pattern of effects on copeptin. 
Another limitation is the retrospective assessment of 
ACE and the cross-sectional design of our study. We 
measured copeptin on only one occasion. We were 
thus unable to deduce whether copeptin might be 
altered in relation to an acute traumatic experience, 
or if copeptin changes precipitate traumatic events, or 
if the level of copeptin and the development of psycho-
pathology are in any way related. We assume that the 
lack of consistency in the field at this point might also 
be due to the heterogeneity of the methods applied 
(pharmacologically induced stress (combined dexa-
methasone/CRH stimulation test), social stressors in 
laboratory settings (TSST), acute real-life stressful 
situations (exams, hospital admissions) as well as 
chronic real-life stressors (childhood maltreatment)) 
and the varying definitions and measures of MDD 
and ACE. We also did not measure osmolality; there-
fore, we could not control for water balance when 
interpreting copeptin concentrations. Additionally, 
establishment of normal ranges and as a clinical para-
meter or biomarker is yet to be implemented.
Research into the association of copeptin with 
psychosocial stress and mental disorders has just 
started. It is not yet known whether increased copep-
tin levels are short-term increases in response to 
acute stress (state marker) or rather reflect long- 
term changes (trait marker). Further studies are 
needed to clarify these issues and to characterize the 
influence of age and sex on copeptin secretion.
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